Natsume et al. summarize approaches with adoptive immunotherapies using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to further develop these therapies.
This article reviews new vaccination protocols against glioblastoma, as well as new the prospect of novel combination therapies.
Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine
In this study, the authors identified SDC-4 as a biomarker to predict clinical outcome using peripheral blood mononuclear cells obtained from patients with glioblastoma, a malignant brain tumor, who were treated with WT1 peptide vaccine.
In this review article, the authors discuss the role of checkpoint inhibition in meningiomas and discuss the future of combined therapeutic strategies.
Ahead of its annual congress, The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) has previewed key sessions at the 32nd edition of the world’s largest congress on multiple sclerosis, taking place from 14–17 September 2016 in London, UK.
A reduction in tumor size of up to 80% has been observed in a current Phase II clinical trial utilizing a newly engineered monoclonal antibody in combination with chemotherapy to treat young, high-risk, neuroblastoma patients.
The results of a Phase III trial have indicated that the addition of a second autologous stem cell transplant to therapy for children with neuroblastoma could improve survival.
Glioblastoma provides a good opportunity for evaluation of immunotherapy as a targeted treatment for patients.
New study highlights potential technique for reducing adverse side effects in Alzheimer’s Disease immunotherapy.